Business Standard

Piramal Group

RBL Bank re-appoints R Subramaniakumar as MD & CEO for a period of 3 years

R Subramaniakumar was initially appointed for a period of three years as MD and CEO of the bank in June 2022

RBL Bank re-appoints R Subramaniakumar as MD & CEO for a period of 3 years
Updated On : 16 Dec 2024 | 6:30 PM IST

Piramal Pharma to pay $407,400 to US-based VetDC Inc to settle dispute

Piramal Pharma on Friday said it will pay USD 407,400 to US-based VetDC, Inc to settle a dispute over rejected batches of a product. Piramal Pharma Solutions Inc, a unit of the company, and VetDC, Inc have entered into a settlement agreement for an amount of USD 407,400, the drug maker said in a regulatory filing. VetDC had claimed damages on account of rejection of certain batches of product manufactured and supplied by Piramal Pharma Solutions Inc. "While the company continues to believe that its legal stand is appropriate against claims made by VetDC and maintains that it has defence to VetDC's claims of liabilities and damages, in order to solely avoid continued legal costs and uncertainties of protracted litigation, the Company and VetDC have both decided to settle," Piramal Pharma said. The company shall have no responsibility for any other costs beyond the amount of USD 407,400, it added. "This settlement will not have a significant impact on the financial position of the .

Piramal Pharma to pay $407,400 to US-based VetDC Inc to settle dispute
Updated On : 07 Dec 2024 | 12:09 AM IST

Piramal Pharma soars 13% on heavy volumes; up 42% in 2 weeks post Q2 show

Till 12:35 pm; a combined 32.3 million shares representing 2.43 per cent of total equity of PPL changed hands on the NSE and BSE.

Piramal Pharma soars 13% on heavy volumes; up 42% in 2 weeks post Q2 show
Updated On : 06 Nov 2024 | 1:06 PM IST

Piramal Pharma deploying $85 mn capex this fiscal: Nandini Piramal

Piramal Pharma is utilising a capex of about USD 85 million for various initiatives, including capacity expansion, maintenance and de-bottlenecking of CDMO sites, in the current fiscal, according to its Chairperson Nandini Piramal. The Mumbai-headquartered firm, which aims to cross USD 2 billion in revenue by FY30, has already invested around USD 30 million in the first half of the ongoing fiscal on the initiatives. "We expect the capex this year to be at a similar level as last year, which is about USD 85 million," Piramal told PTI in an interaction. A part of the capex is planned for the domestic market while some of it would also go into the US business, she added. "Some part of it, around USD 30 million, is maintenance capex, and the rest would go into capacity expansion in Telangana and Dahej (Gujarat) plants and also towards de-bottlenecking of some of the CDMO sites," Piramal noted. The company last week reported over four-fold increase in consolidated net profit at Rs 23 c

Piramal Pharma deploying $85 mn capex this fiscal: Nandini Piramal
Updated On : 27 Oct 2024 | 11:33 PM IST

Piramal Pharma hits all time high, soars 13%; here's what's driving stock

Piramal Pharma's company's revenue for the quarter under review stood at Rs 2,242 crore as compared to Rs 1,911 crore which implies an increase of 17 per cent Y-o-Y

Piramal Pharma hits all time high, soars 13%; here's what's driving stock
Updated On : 24 Oct 2024 | 11:24 AM IST

Pharmaceutical firm Piramal Pharma eyes to double revenue to $2 bn by FY30

Eyeing tripling of Ebitda and bringing down net debt during the same period

Pharmaceutical firm Piramal Pharma eyes to double revenue to $2 bn by FY30
Updated On : 25 Sep 2024 | 11:44 PM IST

Piramal Pharma soars 9% as co targets 2x revenue, 3x Ebitda margin by FY30

Piramal Pharma aims to achieve over $2 billion in revenue by FY30, which implies 2 times growth in revenue compared with FY24

Piramal Pharma soars 9% as co targets 2x revenue, 3x Ebitda margin by FY30
Updated On : 25 Sep 2024 | 1:22 PM IST

Piramal Pharma hits record high in weak market; surges 12% on heavy volumes

As many as 43.42 million equity shares, representing 3.3 per cent of total equity of the pharma company, had changed hands on the NSE till afternoon

Piramal Pharma hits record high in weak market; surges 12% on heavy volumes
Updated On : 04 Sep 2024 | 2:21 PM IST

Piramal Pharma Q1FY25 results: Net loss narrows at Rs 88.64 crore

Piramal Pharma Ltd on Friday reported a narrowing of consolidated net loss at Rs 88.64 crore in the first quarter that ended June 30, 2024, on the back of higher sales. The company had posted a consolidated net loss of Rs 98.58 crore in the same quarter last fiscal, Piramal Pharma said in a regulatory filing. Consolidated revenue from operations in the quarter under review stood at Rs 1,951.14 crore as compared to Rs 1,748.85 crore in the year-ago period, the company added. Total expenses in the first quarter were higher at Rs 2,038.16 crore as compared to Rs 1,908.66 crore in the same period a year ago. "We have had a good start to the financial year with a steady all-round performance...," Piramal Pharma Chairperson Nandini Piramal said. The company's CDMO (Contract Development and Manufacturing Organisation) business continues to witness sustained order inflows, especially for on-patent commercial manufacturing, she added. "We are also seeing good demand for our differentiate

Piramal Pharma Q1FY25 results: Net loss narrows at Rs 88.64 crore
Updated On : 26 Jul 2024 | 11:30 PM IST

Piramal Group refutes data breach claims, terms dark web activity as false

Pharma to financial services conglomerate Piramal Group has denied any data breach in its system. A hacker on dark web last week claimed to be allegedly selling a database belonging to Piramal Group. When contacted, a Piramal spokesperson denied the claim. "We can confirm that there has been no data breach at Piramal Group. The suspicious activity on the dark web was evaluated and confirmed by our cybersecurity team as a false claim," the spokesperson said. The spokesperson said that as per the group's investigation, the sample data shared has no relevance to the group. "As per our investigation, the sample data shared is not Piramal Organization data and has no relevance to us. On further investigation, we have also found that the information in question seems to have originated from a third-party platform, Mailinator and not any of the systems at Piramal. Mailinator is not associated with Piramal Group in any form," the spokesperson said. Piramal Group has also shared the same

Piramal Group refutes data breach claims, terms dark web activity as false
Updated On : 26 Jul 2024 | 7:58 PM IST

Piramal Pharma Q1FY25 results; Loss improves to Rs 89 cr; shares jump 3%

Shares of Piramal Pharma rose 3.51 per cent, reaching their 52-week high at Rs 172.10 per share on the BSE in Friday''s intraday trade

Piramal Pharma Q1FY25 results; Loss improves to Rs 89 cr; shares jump 3%
Updated On : 26 Jul 2024 | 1:42 PM IST

Reliance Industries' subsidiary Ethane plans over $500 mn offshore loan

In 2016, Reliance Ethane had raised a loan of $572 million with a 12-year tenor to purchase six new ethane carriers

Reliance Industries' subsidiary Ethane plans over $500 mn offshore loan
Updated On : 11 Jul 2024 | 2:35 PM IST

Piramal Pharma open to partnerships in OTC; eyes further debt reduction

Piramal said that they are focusing on organic growth across all their verticals - OTC business in India, complex hospital generics, and the Contract Development and Manufacturing (CDMO) business

Piramal Pharma open to partnerships in OTC; eyes further debt reduction
Updated On : 13 May 2024 | 10:36 PM IST

Piramal Group's fund management arm invests Rs 600 cr in Annapurna Finance

The assets under management of Annapurna Finance exceed $1.25 billion as of March 31, 2024, with 1,372 branches spread across 20 states and covering nearly 450 districts

Piramal Group's fund management arm invests Rs 600 cr in Annapurna Finance
Updated On : 13 May 2024 | 6:21 PM IST

Piramal Pharma Q4 profit Jumps 102% to Rs 101.3 cr, FY24 revenue Up 18%

On a sequential basis, the company's profit jumped more than nine-fold

Piramal Pharma Q4 profit Jumps 102% to Rs 101.3 cr, FY24 revenue Up 18%
Updated On : 11 May 2024 | 1:36 PM IST

Piramal Alternatives invests Rs 110 crore in Biodeal Pharmaceuticals

The funding will be utilised to improve Biodeal's infrastructure and production capacity

Piramal Alternatives invests Rs 110 crore in Biodeal Pharmaceuticals
Updated On : 08 Apr 2024 | 6:04 PM IST

Piramal Pharma Q3FY24 results: Company posts profit at Rs 19.3 crore

On a sequential basis, the company exhibited a 2.47 percent increase in revenue whereas the PAT declined by 51.07 percent

Piramal Pharma Q3FY24 results: Company posts profit at Rs 19.3 crore
Updated On : 30 Jan 2024 | 10:28 PM IST

Piramal Enterprises Q3 results: Consolidated net loss stood at Rs 2,378 cr

During the quarter, the group made a regulatory provision of Rs 3,540 crore with regard to its investments in AIFs as per the Reserve Bank of India's (RBI) mandate

Piramal Enterprises Q3 results: Consolidated net loss stood at Rs 2,378 cr
Updated On : 29 Jan 2024 | 4:51 PM IST

As RBI tightens rules, Piramal to set aside funds for AIF exposure

As per the RBI's direction, regulated entities must liquidate their investments in AIFs within 30 days should the fund invest in an existing borrower

As RBI tightens rules, Piramal to set aside funds for AIF exposure
Updated On : 21 Dec 2023 | 5:02 PM IST

Piramal Pharma clocks 11% revenue growth in quarter ending September

Company's Ebitda grows 44% year-on-year, Chairperson Nandini Piramal anticipates a stronger financial performance in H2

Piramal Pharma clocks 11% revenue growth in quarter ending September
Updated On : 28 Oct 2023 | 3:32 PM IST